About the Journal

Aims and Scope

The Journal of Hematologic Oncology & Neuro-Lymphoma Research (J. Hematol. Oncol. Neuro-Lymphoma Res.) is a fully open-access, peer-reviewed journal publishing high-quality original research, systematic reviews, case reports, and clinical trials in hematologic malignancies with particular emphasis on CNS lymphoma and novel therapeutic strategies.

The journal is particularly interested in research addressing:

• Secondary and primary CNS lymphoma, including DLBCL, primary CNS lymphoma, and leptomeningeal disease
• Blood-brain barrier penetration of novel targeted agents and immunotherapies
• Bispecific T-cell engagers and CAR-T therapy in B-cell malignancies
• BCL-2 inhibition, BTK inhibition, and XPO1 inhibition in lymphoma
• Intrathecal and intraventricular drug delivery strategies
• Molecular biomarkers of response and resistance
• Combination regimens in relapsed/refractory settings
• Supportive care, toxicity management, and quality of life in lymphoma

Peer Review Process

All submitted manuscripts undergo double-blind peer review by at least two independent experts. Our structured review process ensures:

• Average first decision within 18 days
• Transparent, constructive reviewer reports
• Opportunity for authors to respond to reviewer comments
• Final editorial decision by section editors with domain expertise
• Post-acceptance production and DOI assignment within 7 days

Open Access & Licensing

All articles are published under the Creative Commons Attribution 4.0 International License (CC BY 4.0), allowing free reuse, distribution, and adaptation for any purpose with appropriate attribution. Authors retain copyright to their work.

Article Processing Charges (APCs)

APC waivers are available for authors from low-income countries as classified by the World Bank. Institutional memberships may provide discounts. Contact editorial@medhorizons.org.

Indexing & Abstracting